Sign in Subscribe
Cybernet Data Systems Inc.

Seattle Genetics Reports on Financial Condition and Results of Operations

Strategic Insights

— 1 min read

Seattle Genetics, a biotechnology company specializing in the development and commercialization of therapies targeting cancer, has reported its quarterly financial condition and results of operations. The company operates through the commercialization of ADCETRIS(R), PADCEV(TM), and TUKYSA(TM), among other products.

The report highlights the company's forward-looking statements, cautioning investors that actual events or results may differ materially. Seattle Genetics operates globally, with ADCETRIS available in over 70 countries and PADCEV co-developed and jointly commercialized with Astellas. The company has active license agreements for its ADC technology with companies such as AbbVie, Genentech, and GlaxoSmithKline.

Key Takeaways:

  • Seattle Genetics has a diverse portfolio of products, including ADCETRIS, PADCEV, and TUKYSA, which are targeted at various types of cancer.
  • The company has active license agreements with prominent pharmaceutical companies, including AbbVie, Genentech, and GlaxoSmithKline, for its ADC technology.
  • PADCEV, co-developed and jointly commercialized with Astellas, received accelerated approval from the FDA in December 2019 for its approved indication.
  • The company is conducting a global, randomized phase 3 clinical trial, called EV-301, to support global registrations for PADCEV.
  • Seattle Genetics has agreements with Genentech for Polivy, an ADC that uses its technology, and with GSK for belantamab mafodotin, which is an additional ADC using its technology.
  • The company is closely evaluating the impact of the COVID-19 pandemic on its operations and the operations of its collaborators.

Statistics:

  • ADCETRIS is commercially available in more than 70 countries.
  • PADCEV is being co-developed and jointly commercialized with Astellas.
  • The global, randomized phase 3 clinical trial, called EV-301, has completed enrollment in January 2020.
  • Seattle Genetics has agreements with Genentech for Polivy and with GSK for belantamab mafodotin.
  • The company has experienced increased competition for virtual appointments with healthcare professionals due to the COVID-19 pandemic.

Sources:

  • Edgar Online via COMTEX
  • Comtex SmarTrend Alert, April 30, 2020
  • Seattle Genetics Form 10-Q, April 30, 2020

Read more